[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopia-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopia-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100652964","children-receiving-monocular-misight-1-day-treatment-for-unilateral-myopia-100652964",false,"NCT07778264","Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia","Natural History and Post-Conversion Clinical Outcomes of the Fellow Eye in Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age 7-18 years.\n2. Cycloplegic SER ≤ -0.75 D in one eye and \\> -0.50 D in the fellow eye.\n3. Cylinder ≤1.00 D in the myopic eye.\n4. BCVA ≥20\u002F25 (0.1 logMAR).\n5. Willingness to wear MiSight® 1 Day for ≥10 hours\u002Fday and ≥6 days\u002Fweek.\n6. Willingness of the participant and parents to comply with the study procedures and complete 12 months of follow-up.\n7. Written informed consent provided by the legal guardian.\n\nExclusion Criteria:\n\n* Previous orthokeratology treatment.\n* Previous atropine treatment exceeding one month.\n* Previous use of other myopia-control soft contact lenses.\n* Keratoconus, corneal degeneration, or other corneal disease.\n* Amblyopia, strabismus, or other significant binocular visual dysfunction.\n* Cataract, glaucoma, uveitis, retinal disease, or other significant ocular disease.\n* Systemic connective-tissue or neurological disease affecting vision.\n* Known allergy to atropine or contact lens materials.\n* Inability to comply with scheduled visits or anticipated relocation during the study period.","ALL","7 Years","18 Years",{"count":20,"type":21},100,"ESTIMATED","100 Months","OBSERVATIONAL","This investigator-initiated prospective observational cohort study aims to establish the first longitudinal clinical database evaluating fellow-eye myopia development in children receiving monocular MiSight® 1 Day treatment for unilateral myopia.\n\nAll myopic eyes will receive MiSight® 1 Day as standard clinical care, while the fellow eye will undergo regular observation without prophylactic intervention. If the fellow eye develops myopia (cycloplegic spherical equivalent ≤ -0.50 D), standard myopia control treatment, including MiSight® 1 Day or 0.05% atropine ophthalmic solution, will be initiated according to routine clinical practice and shared decision-making between the investigator and the child's parents The findings are expected to provide important evidence regarding fellow-eye refractive development, identify predictors of myopia conversion, optimize the timing of intervention, and support personalized myopia management in children with unilateral myopia.",[26,27],"Myopia (Disorder)","Anisometropia","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-09-15",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"Buddhist Tzu Chi General Hospital","OTHER"]